论文部分内容阅读
目的研究分析长春瑞滨联合顺铂化疗治疗对蒽环类耐药乳腺癌患者的临床效果。方法 94例对蒽环类耐药乳腺癌患者,分为对照组和观察组,各47例。对照组采用多西他赛联合顺铂化疗,观察组采用长春瑞滨联合顺铂化疗。比较两组治疗效果。结果观察组缓解率高于对照组,差异有统计学意义(P<0.05);观察组生活质量评分高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论长春瑞滨联合顺铂化疗治疗对蒽环类耐药乳腺癌患者具有较高的临床效果,不良反应少,值得推广。
Objective To study the clinical effect of vinorelbine combined with cisplatin chemotherapy on patients with anthracycline-resistant breast cancer. Methods 94 cases of anthracycline-resistant breast cancer patients, divided into control group and observation group, 47 cases in each. Docetaxel plus cisplatin was used in the control group and vinorelbine plus cisplatin in the observation group. Compare the treatment effect of two groups. Results The remission rate in the observation group was higher than that in the control group (P <0.05), and the quality of life in the observation group was higher than that in the control group (P <0.05). The incidence of adverse reactions in the observation group was lower than Control group, the difference was statistically significant (P <0.05). Conclusion The combination of vinorelbine and cisplatin chemotherapy has a high clinical effect on patients with anthracycline-resistant breast cancer, with fewer adverse reactions and is worthy of promotion.